Fatma Jendoubi1, Maella Severino-Freire1, Mathilde Negretto1, Christophe Arbus2, Carle Paul1, Cristina Bulai Livideanu3. 1. Mastocytosis National Expert Centre (CEREMAST), Department of Dermatology, Toulouse University Hospital, 24 Chemin de Pouvourville, 31059, Toulouse, France. 2. Department of Psychiatry, Toulouse University Hospital, Tonic Inserm 1214, Toulouse, France. 3. Mastocytosis National Expert Centre (CEREMAST), Department of Dermatology, Toulouse University Hospital, 24 Chemin de Pouvourville, 31059, Toulouse, France. livideanu.c@chu-toulouse.fr.
Abstract
BACKGROUND: Mastocytosis is a rare disease characterised by the accumulation and/or proliferation of abnormal mast cells (MCs) in one or several organs. It may present with a number of different symptoms that involve various organ systems. The current study aims to assess the prevalence of MC mediator-related symptoms in a cohort of mastocytosis patients with a specific focus on neurological, psychiatric, cognitive and sexual symptoms. We also assessed the impact of the disease on patients' professional lives. Patients were administered a validated multidimensional questionnaire to collect information on patients' perception of the severity of their symptoms. From the questionnaires we extracted the neurological, cognitive, psychiatric and sexual symptoms and the impact of the disease on patients' professional lives as well as their grading. The affective status was assessed using the 17-item version of the Hamilton Depression Rating Scale. RESULTS: We included 139 patients. Mastocytosis was classified as systemic in 113 patients and cutaneous in 26 patients. The prevalence of MC mediator-related systemic symptoms was as follows: cutaneous (71%), gastro-intestinal (48%), cardio-vascular (36%), musculoskeletal (26.6%), fatigue (24%), urinary (14.4%) and respiratory (10%). Headaches and vertigo were noted in respectively 55% and 32% of patients. Irritability, episodes of memory loss and difficulty concentrating were reported in 54%, 52% and 40% of cases, respectively. Sexual impairment was noted in 24% of patients. No associations were found between neuropsychiatric/cognitive impairment and age, gender, diagnostic delay, disease form, the presence of cutaneous lesions, the level of serum and bone marrow tryptase and the presence of KIT mutation in bone marrow and/or skin. Depression was noted in 49% of patients. One in four patients reported a negative impact of the disease on their professional lives. CONCLUSION: This current study provides some insights regarding symptoms related to mastocytosis and their impact on patients' professional lives.
BACKGROUND:Mastocytosis is a rare disease characterised by the accumulation and/or proliferation of abnormal mast cells (MCs) in one or several organs. It may present with a number of different symptoms that involve various organ systems. The current study aims to assess the prevalence of MC mediator-related symptoms in a cohort of mastocytosispatients with a specific focus on neurological, psychiatric, cognitive and sexual symptoms. We also assessed the impact of the disease on patients' professional lives. Patients were administered a validated multidimensional questionnaire to collect information on patients' perception of the severity of their symptoms. From the questionnaires we extracted the neurological, cognitive, psychiatric and sexual symptoms and the impact of the disease on patients' professional lives as well as their grading. The affective status was assessed using the 17-item version of the Hamilton Depression Rating Scale. RESULTS: We included 139 patients. Mastocytosis was classified as systemic in 113 patients and cutaneous in 26 patients. The prevalence of MC mediator-related systemic symptoms was as follows: cutaneous (71%), gastro-intestinal (48%), cardio-vascular (36%), musculoskeletal (26.6%), fatigue (24%), urinary (14.4%) and respiratory (10%). Headaches and vertigo were noted in respectively 55% and 32% of patients. Irritability, episodes of memory loss and difficulty concentrating were reported in 54%, 52% and 40% of cases, respectively. Sexual impairment was noted in 24% of patients. No associations were found between neuropsychiatric/cognitive impairment and age, gender, diagnostic delay, disease form, the presence of cutaneous lesions, the level of serum and bone marrow tryptase and the presence of KIT mutation in bone marrow and/or skin. Depression was noted in 49% of patients. One in four patients reported a negative impact of the disease on their professional lives. CONCLUSION: This current study provides some insights regarding symptoms related to mastocytosis and their impact on patients' professional lives.
Authors: Peter Valent; Cem Akin; Michel Arock; Knut Brockow; Joseph H Butterfield; Melody C Carter; Mariana Castells; Luis Escribano; Karin Hartmann; Philip Lieberman; Boguslaw Nedoszytko; Alberto Orfao; Lawrence B Schwartz; Karl Sotlar; Wolfgang R Sperr; Massimo Triggiani; Rudolf Valenta; Hans-Peter Horny; Dean D Metcalfe Journal: Int Arch Allergy Immunol Date: 2011-10-27 Impact factor: 2.749
Authors: M Fradet; M Negretto; E Tournier; C Laurent; P A Apoil; S Evrard; Y Degboe; V Del Mas; L Lamant; P Dubreuil; M Laroche; C Mailhol; O Hermine; C Paul; C Bulai Livideanu Journal: J Eur Acad Dermatol Venereol Date: 2019-05-17 Impact factor: 6.166
Authors: Karlynn M Brintzenhofe-Szoc; Tomer T Levin; Yuelin Li; David W Kissane; James R Zabora Journal: Psychosomatics Date: 2009 Jul-Aug Impact factor: 2.386
Authors: C Bulai Livideanu; P A Apoil; B Lepage; M Eischen; C Laurent; P Laharrague; L Lamant; E Tournier; S Tavitian; C Pouplard; C Recher; M Laroche; C Mailhol; P Dubreuil; O Hermine; A Blancher; C Paul Journal: Clin Exp Allergy Date: 2016-01 Impact factor: 5.018
Authors: Duraisamy Kempuraj; Govindhasamy P Selvakumar; Ramasamy Thangavel; Mohammad E Ahmed; Smita Zaheer; Sudhanshu P Raikwar; Shankar S Iyer; Sachin M Bhagavan; Swathi Beladakere-Ramaswamy; Asgar Zaheer Journal: Front Neurosci Date: 2017-12-12 Impact factor: 4.677